Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02187692
Other study ID # MCTPOLAND
Secondary ID
Status Completed
Phase N/A
First received October 14, 2013
Last updated July 10, 2014
Start date August 2012
Est. completion date September 2013

Study information

Verified date October 2013
Source Medical University of Warsaw
Contact n/a
Is FDA regulated No
Health authority Poland: Ethics Committee
Study type Interventional

Clinical Trial Summary

The aim of the study is to compare the effectiveness of the meta-cognitive training (MCT) for schizophrenia against treatment as usual (TAU) among patients who attends community support groups. 4 weeks of MCT will be administered for patients two times per week. MCT consists of well structured cognitive behavioral therapy interventions. MCT will be administered according authors recommendations. All participants will be assessed at baseline (T0) and up to one week after the MCT intervention (T1, 4-5 week of the study).


Description:

50 patients with established schizophrenia diagnosis will be included and randomized into two conditions: MCT (n= 25) and TAU (n=25). Exclusion criteria are: neurological diseases, substance dependence (alcohol and drugs).

A broad outcome measures will be provided including symptoms severity, cognitive biases, neurocognition, insight and social functioning. Changes in variable after the intervention will be compared between two condition.

Only patients with established schizophrenia with no neurological diseases will be included.

All patients will be assessed at two time points: T0 - at baseline, up to one week before the intervention starts and T1 up to one week after the intervention is finished. T1 assessment will be at 4-5 weeks after the study begun.

Measures

1. General functioning General Assessment of Functioning was used as a measure of the severity of patients' functional disabilities.

2. Insigh A questionnaire of insight into schizophrenia consists of six items targeting insight. The scale has a good reliability with Cronbach's alpha 0.8.

3. The subjective sense of influence on the course of schizophrenia The Brief Measure to Assess Perception of the Self-influence on the Disease Course - Version for Schizophrenia consists of five items targeting different aspects of subjective sense of influence on the course of schizophrenia. The scale has satisfactory psychometric properties (Cronbach's alpha= 0.78).

4, Psychotic symptoms The severity of delusions and hallucinations were assessed at the baseline and after the intervention with the semi-structured Psychotic Symptom Rating Scale (The PSYRATS). The PSYRATS comprises hallucination and delusions subscale, each design to assess psychological aspects of the symptoms on a five point scale from 0 to 4. The items for the hallucination scale are: frequency (PH1); duration (PH2); location (PH3); loudness (PH4); beliefs regarding the origin of voices (PH5); amount of negative content of voices (PH6); degree of negative content (PH7); amount of distress (PH8); intensity of distress (PH9); disruption to life caused by voices (PH10); controlability of voices (PH11). The delusion subscale consists of six items: amount of preoccupation with delusions (PD1); duration of preoccupation with delusions (PD2); conviction (PD3); amount of distress (PD4); intensity of distress (PD5); disruption to life caused by beliefs (PD6). The PSYRATS has good psychometric properties and have been reported being sensitive to symptoms change over time. In addition the Paranoia Checklist which comprises 18 items, each rated on 5 point scale for frequency, distress and degree of conviction, was used in order to assess delusional ideations. The participants were asked to state if they experience different delusional ideation during the last week before filling out the questionnaire.

5. Cognitive Biases. Cognitive Biases Questionnaire for Psychosis consists of 30 vignettes of everyday life scenarios. Participants are asked to imagine themselves as being in the situation and then choose one out of four cognitive responses indicating specific cognitive biases. CBQp comprises of seven subscales: anomalous perceptions (AP); threatening events (TE); intentionalising (I); catastrophising (C); dichotomous thinking (DT); jumping to conclusion (JTC); emotion based reasoning (ER).

In addition two behavioral tasks were used in order to assess the most prominent cognitive biases in schizophrenia, that is to say jumping to conclusion and theory of mind deficits. In the Fish Task the participants are presented with two lakes with different proportion of grey and orange fishes. In the first lake (lake A) there is 80% grey and 20% of orange fishes. The proportion of fishes in the lake B is reversed. Participants are presented with the fisherman who stands between lakes to catch fishes, but he is allowed to do that only from one lake during the entire experiment. Participants on the computer screen were presented with fishes. Two responses were gathered: 1) the participant should make the confidence judgment by indicating from 0-100% how confident they are regarding the fish is from lake A or lake B; 2) whether the participant has enough evidences for the final decision on the fish is from lake A or B. Two alternative versions of the Fish Task were used for pre- and post-test. We analyzed a number of fishes that were considered by participants for the final decision. The less fishes were considered the more the participant has jumping to conclusions tendencies.

Reading the Mind from Eyes Test (RMET,) was used in order to assess the deficits in the theory of mind. The test consists of 36 different faces pictures restricted to eyes area only. Based on the face expression participant is asked to infer the emotional state of the person presented on the picture. We split the original 36 pictures test into two separate tests for the pre- and post-test. In addition to original test we included the conviction question in which participants responded how confident they are in their decisions (100% sure). The RMET test has good psychometric properties and has been used often in schizophrenia.

6. Global neurocognitive functioning Trial making test (TMT) A and B was used to assess global cognitive flexibility. TMT A test is design to test psychomotor speed and attention. TMT B test targets the data on the cognitive flexibility.

All tests will be administered at T0 (baseline assessment up to one week before intervention) and T1 (up to one week after the intervention ).


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- schizophrenia diagnosis accotding to the ICD-10 criteria

- attending local community support groups for psychitatric patients

Exclusion Criteria:

- neurological diseases

- substance abuse

- severe psychotic symptoms

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
MCT
The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.

Locations

Country Name City State
Poland II Department of Psychiatry, Medical University of Warsaw Warsaw

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Warsaw

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Other Neurocognition Trial making test (TMT) A and B was used to assess global cognitive flexibility. TMT A test is design to test psychomotor speed and attention. TMT B test targets the data on the cognitive flexibility. week 0 No
Other [Change] Neurocognition Trial making test (TMT) A and B was used to assess global cognitive flexibility. TMT A test is design to test psychomotor speed and attention. TMT B test targets the data on the cognitive flexibility. week 4-5 No
Primary Psychotic Symptom Rating Scale (The PSYRATS) The severity of delusions and hallucinations were assessed at the baseline and after the intervention with the semi-structured Psychotic Symptom Rating Scale. The PSYRATS comprises hallucination and delusions subscale, each design to assess psychological aspects of the symptoms on a five point scale from 0 to 4. week 0 No
Primary [change] Psychotic Symptom Rating Scale (The PSYRATS) The severity of delusions and hallucinations were assessed at the baseline and after the intervention with the semi-structured Psychotic Symptom Rating Scale. The PSYRATS comprises hallucination and delusions subscale, each design to assess psychological aspects of the symptoms on a five point scale from 0 to 4. week 4-5 No
Secondary Cognitive Biases Questionnairre for Psychosis (CBQp) Cognitive Biases Questionnaire for Psychosis (CBQp) consists of 30 vignettes of everyday life scenarios. Participants are asked to imagine themselves as being in the situation and then choose one out of four cognitive responses indicating specific cognitive biases. CBQp comprises of seven subscales: anomalous perceptions (AP); threatening events (TE); intentionalising (I); catastrophising (C); dichotomous thinking (DT); jumping to conclusion (JTC); emotion based reasoning (ER). week 0 No
Secondary [Change] Cognitive Biases Questionnairre for Psychosis (CBQp) Cognitive Biases Questionnaire for Psychosis (CBQp) consists of 30 vignettes of everyday life scenarios. Participants are asked to imagine themselves as being in the situation and then choose one out of four cognitive responses indicating specific cognitive biases. CBQp comprises of seven subscales: anomalous perceptions (AP); threatening events (TE); intentionalising (I); catastrophising (C); dichotomous thinking (DT); jumping to conclusion (JTC); emotion based reasoning (ER). week 4-5 No
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A